Mink Therapeutics Inc (INKT)

$14.21 +0.08 (0.57%)
Market Cap 70.17M
Revenue (ttm) 0.00
Net Income (ttm) -12.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 151,600
Avg Vol 367,934
Day's Range N/A - N/A
Shares Out 4.97M
Stochastic %K 83%
Beta 0.35
Analysts Strong Sell
Price Target $39.00

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilim...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 994 8250
Address:
149 Fifth Avenue, Suite 500, New York, United States
Tigertkbc
Tigertkbc Apr. 17 at 9:42 PM
$INKT So not meeting ORR is entirely related to Inkt?
0 · Reply
BenUnknown
BenUnknown Apr. 17 at 8:26 PM
$INKT interesting survival signals. Bummer they missed the ORR. Curious to see how investors / share price react
2 · Reply
Goodstockday
Goodstockday Apr. 17 at 7:36 PM
$INKT These results are not great. Specific OS data not reported. Need more information, but they seem to be hiding big stuff.
0 · Reply
Spartrap
Spartrap Apr. 17 at 7:35 PM
$INKT great data in the induction arms! (meaning the 2 arms that had their first cycle begin with an agenT-797 and/or Boat+bal induction) So this validates the immune priming thesis. "Median overall survival (OS) was 9.5 months in the induction cohort versus 5.2 months without induction, with 43% of induction-treated patients alive at both 12 and 18 months, compared with 20% and 0%, respectively, in the non-induction cohort." The survival difference is huge. Sadly the Overall Response Rate didn't meet the criteria so the data is not so easy to interpret from the market standpoint - the way forward isn't as straightforward as when the primary endpoint is met
0 · Reply
pedmac2000
pedmac2000 Apr. 17 at 7:33 PM
$INKT what the better buy Agenus or mink?
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Apr. 17 at 7:15 PM
$AGEN still time to buy the $INKT data https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-reports-phase-ii-data-immune-reprogramming-and
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Apr. 17 at 7:10 PM
$INKT Home run! .19 HR !! 6.9mos!
0 · Reply
Tigertkbc
Tigertkbc Apr. 17 at 7:02 PM
$INKT What was that??
0 · Reply
BenUnknown
BenUnknown Apr. 17 at 6:20 PM
$INKT added again👊🏼🥂
0 · Reply
uptrend2025
uptrend2025 Apr. 17 at 5:55 PM
$INKT Cancer presentation this weekend 👀
0 · Reply
Latest News on INKT
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

Apr 3, 2026, 7:30 AM EDT - 15 days ago

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

Apr 1, 2026, 7:30 AM EDT - 17 days ago

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

Mar 31, 2026, 7:30 AM EDT - 18 days ago

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

Mar 17, 2026, 7:30 AM EDT - 4 weeks ago

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?

Mar 11, 2026, 9:24 AM EDT - 5 weeks ago

Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?

MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally

Mar 10, 2026, 9:47 AM EDT - 5 weeks ago

MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

Mar 10, 2026, 5:30 AM EDT - 5 weeks ago

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

Feb 3, 2026, 9:30 PM EST - 2 months ago

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

Jan 8, 2026, 12:00 PM EST - 3 months ago

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

Nov 20, 2025, 11:42 AM EST - 5 months ago

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Nov 7, 2025, 9:00 AM EST - 5 months ago

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

Sep 29, 2025, 7:30 AM EDT - 7 months ago

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

Sep 25, 2025, 7:30 AM EDT - 7 months ago

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

Sep 18, 2025, 7:30 AM EDT - 7 months ago

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Aug 14, 2025, 7:30 AM EDT - 8 months ago

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

Jul 31, 2025, 8:30 AM EDT - 9 months ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Jul 15, 2025, 8:21 AM EDT - 9 months ago

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

Jul 11, 2025, 12:33 PM EDT - 10 months ago

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:33 PM EDT - 11 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

Jun 2, 2025, 9:29 AM EDT - 11 months ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

May 15, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mar 18, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Mar 4, 2025, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 24, 2025, 8:30 AM EST - 1 year ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 1 year ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Jan 23, 2025, 2:13 PM EST - 1 year ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Dec 18, 2024, 9:45 AM EST - 1 year ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 11, 2024, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Nov 7, 2024, 10:00 AM EST - 1 year ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 31, 2024, 9:15 AM EDT - 1 year ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 8, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Oct 4, 2024, 9:10 AM EDT - 1 year ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Sep 3, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Second Quarter 2024 Results and Business Update

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Aug 1, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

Jul 31, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 22, 2024, 7:30 AM EDT - 2 years ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

MiNK Reports First Quarter 2024 Results

May 14, 2024, 7:30 AM EDT - 2 years ago

MiNK Reports First Quarter 2024 Results

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

May 13, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 30, 2024, 7:30 AM EDT - 2 years ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Apr 8, 2024, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 21, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 7, 2024, 7:30 AM EST - 2 years ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

Mar 6, 2024, 8:30 AM EST - 2 years ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Jan 30, 2024, 8:00 AM EST - 2 years ago

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Dec 20, 2023, 7:30 AM EST - 2 years ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

MiNK Therapeutics Reports Third Quarter 2023 Results

Nov 9, 2023, 7:00 AM EST - 2 years ago

MiNK Therapeutics Reports Third Quarter 2023 Results

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Nov 3, 2023, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Oct 30, 2023, 8:00 AM EDT - 2 years ago

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Sep 27, 2023, 9:05 AM EDT - 2 years ago

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Tigertkbc
Tigertkbc Apr. 17 at 9:42 PM
$INKT So not meeting ORR is entirely related to Inkt?
0 · Reply
BenUnknown
BenUnknown Apr. 17 at 8:26 PM
$INKT interesting survival signals. Bummer they missed the ORR. Curious to see how investors / share price react
2 · Reply
Goodstockday
Goodstockday Apr. 17 at 7:36 PM
$INKT These results are not great. Specific OS data not reported. Need more information, but they seem to be hiding big stuff.
0 · Reply
Spartrap
Spartrap Apr. 17 at 7:35 PM
$INKT great data in the induction arms! (meaning the 2 arms that had their first cycle begin with an agenT-797 and/or Boat+bal induction) So this validates the immune priming thesis. "Median overall survival (OS) was 9.5 months in the induction cohort versus 5.2 months without induction, with 43% of induction-treated patients alive at both 12 and 18 months, compared with 20% and 0%, respectively, in the non-induction cohort." The survival difference is huge. Sadly the Overall Response Rate didn't meet the criteria so the data is not so easy to interpret from the market standpoint - the way forward isn't as straightforward as when the primary endpoint is met
0 · Reply
pedmac2000
pedmac2000 Apr. 17 at 7:33 PM
$INKT what the better buy Agenus or mink?
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Apr. 17 at 7:15 PM
$AGEN still time to buy the $INKT data https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-reports-phase-ii-data-immune-reprogramming-and
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Apr. 17 at 7:10 PM
$INKT Home run! .19 HR !! 6.9mos!
0 · Reply
Tigertkbc
Tigertkbc Apr. 17 at 7:02 PM
$INKT What was that??
0 · Reply
BenUnknown
BenUnknown Apr. 17 at 6:20 PM
$INKT added again👊🏼🥂
0 · Reply
uptrend2025
uptrend2025 Apr. 17 at 5:55 PM
$INKT Cancer presentation this weekend 👀
0 · Reply
Spartrap
Spartrap Apr. 17 at 3:01 PM
$INKT AACR this weekend, with news in Gastric Cancer, 2 years worth of data, n=37, solid mechanistic rationale, very interesting study in combo with $AGEN drugs. https://clinicaltrials.gov/study/NCT06251973?term=Agent-797&viewType=Card&rank=4
2 · Reply
ghcb1981
ghcb1981 Apr. 17 at 12:56 PM
$INKT
0 · Reply
janed102
janed102 Apr. 17 at 12:08 PM
$INKT $IBRX
0 · Reply
ghcb1981
ghcb1981 Apr. 17 at 9:30 AM
$INKT
0 · Reply
ghcb1981
ghcb1981 Apr. 17 at 7:57 AM
$INKT
0 · Reply
Rach7117
Rach7117 Apr. 17 at 12:56 AM
$INKT only 1 m in the float!?
0 · Reply
BenUnknown
BenUnknown Apr. 16 at 9:13 PM
$IBRX $INKT !!!
0 · Reply
janed102
janed102 Apr. 16 at 8:43 PM
$IBRX get into $INKT before it's too late.. The synergy between MiNK and ImmunityBio centers on "Immunotherapy 2.0," which combines iNKT cells with lymphocyte-stimulating agents like Anktiva. Patrick is involved
1 · Reply
enkemm
enkemm Apr. 16 at 7:29 PM
$INKT Really Biotechguy...back to spew more venom regarding AGEN & INKT. It makes sense that you would invest much as you are endowed...SHORT.
0 · Reply
janed102
janed102 Apr. 16 at 7:25 PM
$INKT I am here.. lets go..
0 · Reply
Astrid00
Astrid00 Apr. 16 at 4:15 PM
$AGEN $IBRX $INKT
0 · Reply
Guptasulo
Guptasulo Apr. 16 at 3:40 PM
$INKT $AGEN $IBRX The next wave in cancer treatment won’t be another Keytruda clone. It will be therapies that work where Keytruda fails — in cold, refractory tumors. MiNK Therapeutics + Agenus + ImmunityBio This is immune system reprogramming, not just checkpoint blocking. That’s where the real disruption begins with groundbreaking treatments.
1 · Reply